NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading BNGO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. BNGO is currently loss-making and faces high risk, but it operates in a sector with positive momentum that could support its growth.
The market seems to have priced in a low level of fragility, indicating that expectations are somewhat justified. BNGO is seen as cheap compared to its peers, but there is a notable expectations gap.
Management is focused on achieving revenue targets and improving operating income, showing some progress in recent quarters. However, the company remains loss-making, and there is a near-term risk of missing earnings expectations.
The thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX. If these companies continue to perform well, it could provide a favorable environment for BNGO. Conversely, any negative guidance from these peers could impact BNGO's outlook.
Over the next 1 to 3 years, BNGO's performance will depend on its ability to meet revenue goals and the broader healthcare sector's health. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This revenue range is a key target for management. Meeting it shows growth momentum.
Confirms:Q2 2026 revenue reported within the range of $7.5 million to $7.8 million.
Disproves:Q2 2026 revenue reported below $7.5 million.
Why it matters: Earnings results will show how revenue and operating income are doing.
Confirms one read:The earnings report shows revenue is growing. It also shows better operating income.
Confirms the other:The earnings report shows revenue is falling. It also shows worse operating income.
Why it matters: Confirming the $30-$33 million revenue guidance is important for investor trust. It shows management wants to grow.
Confirms:Management confirms full year 2026 revenue guidance of $30-$33 million.
Disproves:Management lowers the full year 2026 revenue guidance.
Why it matters: A new CEO can bring new ideas and stability after recent changes.
Confirms:A new CEO with industry experience has been announced.
Disproves:No new CEO announced by the next earnings date.
Why it matters: The CEO change may change the company direction and affect investor trust.
Confirms one read:New CEO outlines a clear strategy that aligns with revenue goals.
Confirms the other:New CEO does not show a clear plan or causes more instability.
Why it matters: Higher operating income means more profit. This shows better financial health.
Confirms:Operating income was less negative than -$7.897 million in Q2 2026.
Disproves:Operating income remains negative at -$7.897 million or worse in Q2 2026.
Why it matters: A new CEO can help the company after recent changes in leadership.
Confirms one read:Announcement of a new CEO or interim leadership plan within the next month.
Confirms the other:There are no updates on the CEO search or leadership issues.
Why it matters: Total revenue growth is crucial for meeting the full year target of $30-$33 million.
Confirms:Total revenue reported above $7.5 million in Q2 2026.
Disproves:Total revenue reported below $7.5 million in Q2 2026.
Why it matters: New partnerships may help Bionano's market position and grow OGM uses.
Confirms:At least one new strategic partnership focused on OGM has been announced.
Disproves:No new strategic partnerships announced in the next quarter.
